Two-sample Mendelian randomization analysis of the causal relationship between lipid metabolism/fatty acid metabolism and pre-eclampsia
Abstract
Objectives: A causal relationship has been found between the abundance of some flora in the gut microbiota and the development of pre-eclampsia (PE). Short-chain fatty acids in gut microbes are an important source of lipids. The causal effect of lipid metabolism/fatty acid metabolism pathways on PE exposure is unknown.
Material and methods: This study was based on single nucleotide polymorphism (SNP) data related to lipid metabolism/fatty acid metabolism and PE from the genome-wide association study (GWAS) in the GWAS Catalog database and finngen database, and a two-sample mendelian randomization (MD) analysis was performed to explore the causal relationship between lipid/fatty acid metabolism and PE exposure. Five MD analysis methods were used in this study, inverse-variance weighted (IVW), MR-Egger regression, weighted median (WM), weighted median estimator (WME), MR-PRESSO. The intercept term of MR-Egger regression was tested for the presence of genetic pleiotropy between SNPs and PEs. Cochran's Q test was performed to investigate the heterogeneity between variables. The leave-one-out method was used for sensitivity analysis to determine the robustness of the results.
Results: Inverse-variance weighted results showed that gamma-glutamyl glutamine levels [odds ratio (OR) = 0.40, 95% confidence interval (CI): 0.21–0.78; p = 0.01], 1-arachidonoylglycerophosphocholine [1-arachidonoyl-sn-glycero-3-phosphocholine levels (OR = 0.57; 95% CI: 0.38–0.87; p = 0.01), X-14304--leucylalanine levels (OR = 0.72; 95% CI :0.56–0.93; p = 0.01), citrulline levels (OR = 0.48; 95% CI: 0.26–0.89; p = 0.02), inosine levels (OR = 0.88; 95% CI: 0.78–0.98; p = 0.02), and HWESASXX levels (OR = 0.64; 95% CI: 0.42–1.00; p = 0.05) were negatively correlated with PE. There was a positive trend for X-14205--alpha-glutamyltyrosine levels (OR = 1.55; 95% CI: 1.12–2.14; p = 0.01), X-11787 levels (OR = 3.29; 95% CI: 1.23–8.78; p = 0.02) to be associated with PE. No significant heterogeneity or pleiotropy was found for instrumental variables or levels pleiotropy.
Conclusions: This study demonstrated a causal relationship between eight fatty acid metabolisms and PE. Follow-up in-depth randomized controlled trials are needed to reveal the promotional or protective effects of fatty acid metabolism on PE.
Keywords: pre-eclampsiamendelian randomizationlipid metabolismfatty acid metabolismgenetic
References
- Chappell L, Cluver C, Kingdom J, et al. Pre-eclampsia. Lancet. 2021; 398(10297): 341–354.
- Dimitriadis E, Rolnik DL, Zhou W, et al. Pre-eclampsia. Nat Rev Dis Primers. 2023; 9(1): 8.
- Burton GJ, Redman CW, Roberts JM, et al. Pre-eclampsia: pathophysiology and clinical implications. BMJ. 2019; 366: l2381.
- Hauspurg A, Jeyabalan A. Postpartum preeclampsia or eclampsia: defining its place and management among the hypertensive disorders of pregnancy. Am J Obstet Gynecol. 2022; 226(2S): S1211–S1221.
- Shen L, Martinez-Portilla RJ, Rolnik DL, et al. ASPRE trial: risk factors for development of preterm pre-eclampsia despite aspirin prophylaxis. Ultrasound Obstet Gynecol. 2021; 58(4): 546–552.
- Ahmed A, Williams DJ, Cheed V, et al. Pravastatin for early-onset pre-eclampsia: a randomised, blinded, placebo-controlled trial. BJOG. 2020; 127(4): 478–488.
- Cluver CA, Hiscock R, Decloedt EH, et al. Use of metformin to prolong gestation in preterm pre-eclampsia: randomised, double blind, placebo controlled trial. BMJ. 2021; 374: n2103.
- Kivelä J, Sormunen-Harju H, Girchenko PV, et al. Longitudinal metabolic profiling of maternal obesity, gestational diabetes, and hypertensive pregnancy disorders. J Clin Endocrinol Metab. 2021; 106(11): e4372–e4388.
- Cui J, Wang J, Wang Y. The role of short-chain fatty acids produced by gut microbiota in the regulation of pre-eclampsia onset. Front Cell Infect Microbiol. 2023; 13: 1177768.
- Bowden J, Holmes MV. Meta-analysis and mendelian randomization: a review. Res Synth Methods. 2019; 10(4): 486–496.
- Sekula P, Del Greco M F, Pattaro C, et al. Mendelian randomization as an approach to assess causality using observational data. J Am Soc Nephrol. 2016; 27(11): 3253–3265.
- Birney E. Mendelian randomization. Cold Spring Harb Perspect Med. 2022; 12(4): a041302.
- Faber BG, Frysz M, Boer CG, et al. The identification of distinct protective and susceptibility mechanisms for hip osteoarthritis: findings from a genome-wide association study meta-analysis of minimum joint space width and Mendelian randomisation cluster analyses. EBioMedicine. 2023; 95: 104759.
- Yang J, Liu P, Wang S, et al. Causal relationship between sarcopenia and osteoarthritis: a bi-directional two-sample mendelian randomized study. Eur J Med Res. 2023; 28(1): 327.
- Su D, Ai Y, Zhu G, et al. Genetically predicted circulating levels of cytokines and the risk of osteoarthritis: a mendelian randomization study. Front Genet. 2023; 14: 1131198.
- Li P, Wang H, Guo L, et al. Association between gut microbiota and preeclampsia-eclampsia: a two-sample Mendelian randomization study. BMC Med. 2022; 20(1): 443.
- Shin SY, Fauman EB, Petersen AK, et al. An atlas of genetic influences on human blood metabolites. Nat Genet. 2014; 46(6): 543–550.
- Hemani G, Zheng J, Elsworth B, et al. The MR-Base platform supports systematic causal inference across the human phenome. Elife. 2018; 7.
- Gestational hypertension and preeclampsia: ACOG practice bulletin summary, number 222. Obstet Gynecol. 2020; 135(6): 1492–1495.
- Ding X, Yang Zi, Han Y, et al. Correlation of long-chain fatty acid oxidation with oxidative stress and inflammation in pre-eclampsia-like mouse models. Placenta. 2015; 36(12): 1442–1449.
- Wotherspoon AC, Young IS, McCance DR, et al. Serum fatty acid binding protein 4 (FABP4) predicts pre-eclampsia in women with type 1 diabetes. Diabetes Care. 2016; 39(10): 1827–1829.
- Chen X, Li P, Liu M, et al. Gut dysbiosis induces the development of pre-eclampsia through bacterial translocation. Gut. 2020; 69(3): 513–522.
- Huang L, Liu Z, Wu P, et al. Puerariae lobatae radix alleviates pre-eclampsia by remodeling gut microbiota and protecting the gut and placental barriers. Nutrients. 2022; 14(23).
- Yong W, Zhao Y, Jiang X, et al. Sodium butyrate alleviates pre-eclampsia in pregnant rats by improving the gut microbiota and short-chain fatty acid metabolites production. J Appl Microbiol. 2022; 132(2): 1370–1383.
- Jin J, Gao L, Zou X, et al. Gut dysbiosis promotes preeclampsia by regulating macrophages and trophoblasts. Circ Res. 2022; 131(6): 492–506.
- Liu C, Wang W, Parchim N, et al. Tissue transglutaminase contributes to the pathogenesis of preeclampsia and stabilizes placental angiotensin receptor type 1 by ubiquitination-preventing isopeptide modification. Hypertension. 2014; 63(2): 353–361.
- Nahas AMEl, Abo-Zenah H, Skill NJ, et al. Elevated ε-(γ-Glutamyl)lysine in human diabetic nephropathy results from increased expression and cellular release of tissue transglutaminase. Nephron Clinical Practice. 2004; 97(3): c108–c117.
- Iloki-Assanga S, McCarty MF. Nutraceutical targeting of placental synthesis of soluble fms-like tyrosine kinase- 1 (sFlt-1) as strategy for preventing and controlling pre-eclampsia. Curr Pharm Des. 2018; 24(20): 2255–2263.
